# Aron Goldhirsch

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/aron-goldhirsch/

## Facts

| Field | Value |
| --- | --- |
| Citations | 72,618 |
| Field | Breast Cancer Treatment Studies |
| h-index | 122 |
| i10-index | 421 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5112472336 |
| Works | 756 |

## Researcher papers

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015](https://scholariq.org/papers/tailoring-therapies-improving-the-management-of-early-breast-cancer-st-gallen/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis](https://scholariq.org/papers/cancer-immunotherapy-efficacy-and-patients-sex-a-systematic-review-and-meta/)
- [Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update](https://scholariq.org/papers/recommendations-from-an-international-expert-panel-on-the-use-of-neoadjuvant/)
- [Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/sex-based-heterogeneity-in-response-to-lung-cancer-immunotherapy-a-systematic/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)
- [Breast phyllodes tumor: A review of literature and a single center retrospective series analysis](https://scholariq.org/papers/breast-phyllodes-tumor-a-review-of-literature-and-a-single-center-retrospective/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.